Rare fusions involving genes, such as EGFR, FGFR, MET, HER2, BRAF, NRG and others were also observed in a small subset of treatment-naïve NSCLC cases, potentially offering new therapeutic options [40]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.